Developer of next-generation transdermal drug delivery patches, Medherant, has signed an agreement with a Japanese transdermal patch company to evaluate the potential of the TEPI Patch technology.
Agreement
As a part of this agreement, Medherant will apply its proprietary high-throughput system for skin permeation studies to evaluate a range of potential formulations of a drug provided by the Japanese company. If the outcome is successful, the Japanese company may license the TEPI Patch technology to develop a product for market.
“We have developed a very good relationship with the company and are delighted to begin this feasibility study,” said Nigel Davis, CEO, Medherant. “We are confident that we will rapidly create a comprehensive data set that will demonstrate the merits of our TEPI Patch technology.”
TEPI Patches are formulated by mixing the drug with a novel adhesive. It is the adhesive that enables high drug loading, allowing lower potency drugs to be delivered and providing the option to include excipients that facilitate the movement of the drug through the skin.